What’s new in coeliac disease? Presented by: Dr Jason Tye-Din, MBBS, PhD, FRACP
In just over an hour, Dr Tye-Din reviews our knowledge to date and explains and clarifies the latest developments in coeliac disease.
Coeliac disease results from a loss of immune tolerance to gluten which results in an autoimmune attack on the body. Coeliac disease is not a food allergy.
In his presentation Dr Tye-Din explains:
- The current diagnostic approach to coeliac disease (and its limitations).
- Gastroscopy and biopsy are the “Gold Standard” test for diagnosing coeliac disease – BUT are only reliable only with adequate bowel sampling and expert pathological processing and interpretation.
- The short and long-term effects of gluten on people with coeliac disease.
- What steps to take if your client has already commenced a gluten free diet but has not been diagnosed with coeliac disease.
- The prevalence of coeliac disease world-wide, with the highest prevalence in Angola, Africa.
- The range of genes and environmental factors which are important in the development of coeliac disease.
- A detailed description of managing the non-responsive coeliac patient (see slides)
- The important work of Coeliac Australia and the many resources available for health professionals
- How and when the gluten immunogenic peptide (GIP) assay can be used to provide objective confirmation of gluten ingestion
- Dietary controversies e.g. gluten contamination elimination diet, 20ppm vs no detectable gluten
- Novel non-dietary treatment approaches e.g. glutenases, coeliac vaccine
Dr Tye-Din is a gastroenterologist with a clinical and research interest in coeliac disease. He heads the Coeliac Research Lab at the Walter and Eliza Hall Institute, runs a coeliac clinic at the Royal Melbourne Hospital and is an Honorary Research Fellow at the Murdoch Children’s Research Institute. His PhD employed feeding studies to characterise gluten immunity that underpinned development of a novel immunotherapy for coeliac disease, Nexvax2. His research interests include understanding the immune and genetic basis for coeliac disease and how gluten tolerance is lost, the role of the microbiome, understanding why the gluten-free diet can fail, and developing and testing novel diagnostics and treatments. He is on the editorial board of Alimentary Pharmacology and Therapeutics and consults for an industry partner (ImmusanT Inc.) who are leading the development of Nexvax2. Jason chairs the Medical Advisory Committee of Coeliac Australia and is involved in patient advocacy, clinical guideline development and medical education.
To register for the webinar and associated documents including the assessment quiz click here